Christophe Corpechot

List of Publications by Year
in descending order

85	11,135	61984 43	54911 84
papers	citations	h-index	g-index

86	86	86	7965
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature, 1996, 383, 707-710.	27.8	1,893
2	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology, 2017, 67, 145-172.	3.7	889
3	Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet, The, 1997, 350, 1511-1515.	13.7	651
4	Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology, 2008, 48, 871-877.	7.3	552
5	Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology, 2002, 35, 1010-1021.	7.3	416
6	Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology, 2006, 43, 1118-1124.	7.3	401
7	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. New England Journal of Medicine, 2018, 378, 2171-2181.	27.0	383
8	The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology, 2005, 128, 297-303.	1.3	367
9	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	1.3	365
10	Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. Journal of Hepatology, 2011, 55, 1361-1367.	3.7	353
11	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	1.3	330
12	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology, 2012, 56, 198-208.	7.3	277
13	Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Annals of the Rheumatic Diseases, 2019, 78, 209-217.	0.9	273
14	The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology, 2000, 32, 1196-1199.	7.3	265
15	Baseline Values and Changes in Liver Stiffness Measured by Transient Elastography Are Associated With Severity of Fibrosis and Outcomes of Patients With Primary Sclerosing Cholangitis. Gastroenterology, 2014, 146, 970-979.e6.	1.3	232
16	Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. Journal of Hepatology, 2010, 53, 162-169.	3.7	197
17	Hepatocellular Hypoxia-Induced Vascular Endothelial Growth Factor Expression and Angiogenesis in Experimental Biliary Cirrhosis. American Journal of Pathology, 1999, 155, 1065-1073.	3.8	189
18	Notch3 Mutations in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), a Mendelian Condition Causing Stroke and Vascular Dementia. Annals of the New York Academy of Sciences, 1997, 826, 213-217.	3.8	157

#	Article	IF	Citations
19	Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology, 2006, 44, 85-90.	7.3	153
20	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 71, 357-365.	3.7	148
21	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	12.1	139
22	Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut, 2020, 69, 92-102.	12.1	136
23	Genetic factors of susceptibility and of severity in primary biliary cirrhosis. Journal of Hepatology, 2008, 49, 1038-1045.	3.7	115
24	Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy. Ultrasound in Medicine and Biology, 2016, 42, 92-103.	1.5	115
25	Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: A study of 156 consecutive patients. Hepatology, 2013, 58, 1105-1110.	7.3	105
26	Radiologic course of primary sclerosing cholangitis: Assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology, 2014, 59, 242-250.	7.3	102
27	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology, 2015, 61, 1041-1055.	7.3	102
28	Largeâ€scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology, 2017, 65, 152-163.	7.3	93
29	Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. Journal of Hepatology, 2015, 63, 1449-1458.	3.7	84
30	Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: A prospective magnetic resonance imaging and histological study. Hepatology, 2009, 50, 528-537.	7.3	83
31	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology, 2019, 156, 96-107.e1.	1.3	82
32	Fetal microchimerism in primary biliary cirrhosis. Journal of Hepatology, 2000, 33, 696-700.	3.7	77
33	Hepatocyte Growth Factor and c-Met Inhibition by Hepatic Cell Hypoxia. American Journal of Pathology, 2002, 160, 613-620.	3.8	76
34	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. American Journal of Gastroenterology, 2020, 115, 1066-1074.	0.4	74
35	Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 296-306.	1.5	69
36	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Alimentary Pharmacology and Therapeutics, 2019, 50, 1127-1136.	3.7	66

#	Article	IF	Citations
37	Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. Journal of Hepatology, 2012, 56, 218-224.	3.7	65
38	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology, 2018, 113, 254-264.	0.4	64
39	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology, 2016, 63, 644-659.	7.3	57
40	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	7.3	55
41	Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology, 2021, 75, 565-571.	3.7	53
42	Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver International, 2009, 29, 857-864.	3.9	49
43	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of Hepatology, 2020, 73, 559-565.	3.7	47
44	Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. PLoS ONE, 2016, 11, e0164224.	2.5	45
45	Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2785-2792.e3.	4.4	43
46	Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCAâ€treated patients with primary biliary cirrhosis. Liver International, 2004, 24, 187-193.	3.9	41
47	Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: Frenchâ€“Spanish experience. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 521-528.	1.5	40
48	Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 570-576.	1.5	38
49	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficultâ€toâ€treat primary biliary cholangitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 1138-1146.	3.7	37
50	Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction. American Journal of Gastroenterology, 1998, 93, 2586-2588.	0.4	36
51	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	3.7	33
52	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1688-1697.e14.	4.4	30
53	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut, 2020, 69, 1502-1509.	12.1	28
54	Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis?. Journal of Hepatology, 2001, 35, 324-328.	3.7	27

#	Article	IF	Citations
55	Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. Gut, 2016, 65, 1230-1232.	12.1	27
56	Genetic contribution of ABCC2 to Dubinâ€Johnson syndrome and inherited cholestatic disorders. Liver International, 2020, 40, 163-174.	3.9	27
57	Geotherapeutics of primary biliary cirrhosis: Bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom. Hepatology, 2007, 46, 963-965.	7.3	25
58	The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 1878-1885.	0.4	24
59	Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities. JHEP Reports, 2021, 3, 100201.	4.9	24
60	Primary biliary cirrhosis: proposal for a new simple histological scoring system. Liver International, 2015, 35, 652-659.	3.9	22
61	The genetic architecture of primary biliary cholangitis. European Journal of Medical Genetics, 2021, 64, 104292.	1.3	18
62	Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid. Seminars in Liver Disease, 2016, 36, 015-026.	3.6	17
63	New treatments/targets for primary biliary cholangitis. JHEP Reports, 2019, 1, 203-213.	4.9	17
64	Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases. Clinics in Liver Disease, 2016, 20, 143-158.	2.1	16
65	Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy. Clinical Gastroenterology and Hepatology, 2021, 19, 2241-2251.e1.	4.4	14
66	Quality of life and illness perception in primary biliary cirrhosis: A controlled cross-sectional study. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 52-58.	1.5	11
67	Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis. Gut, 2019, 68, 1902-1903.	12.1	10
68	Promoter polymorphism of the CD14 endotoxin receptor gene and primary biliary cirrhosis. Hepatology, 2002, 35, 242-243.	7.3	9
69	Elastography-based assessment of primary biliary cirrhosis staging. Digestive and Liver Disease, 2011, 43, 839-840.	0.9	9
70	Rate of Spleen Length Progression Is a Marker of Outcome in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2613-2615.	4.4	8
71	Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate addâ€on in primary biliary cholangitis with incomplete UDCA response. Alimentary Pharmacology and Therapeutics, 2019, 49, 236-238.	3.7	8
72	Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 387-394.	1.5	7

#	Article	IF	Citations
73	TNF-Î± antagonist infliximab for aseptic abscess syndrome. Presse Medicale, 2019, 48, 1579-1580.	1.9	7
74	The Role of Fibrates in Primary Biliary Cholangitis. Current Hepatology Reports, 2019, 18, 107-114.	0.9	6
75	Intrahepatic cystic biliary dilatation constitutes a significant prognostic factor in patients with primary sclerosing cholangitis. European Radiology, 2019, 29, 1460-1468.	4.5	6
76	Primary biliary cirrhosis: Is there still a place for histological evaluation?. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 556-558.	1.5	5
77	Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience. Journal of Hepatology, 2020, 72, 1210-1211.	3.7	4
78	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY BILIARY CHOLANGITIS. Clinics and Research in Hepatology and Gastroenterology, 2021, 46, 101770.	1.5	4
79	Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium. European Journal of Gastroenterology and Hepatology, 2021, 33, e197-e205.	1.6	4
80	Clinical Trials in PBC Going Forward. Seminars in Liver Disease, 2019, 39, e1-e6.	3.6	3
81	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	1.6	2
82	Reply. Hepatology, 2017, 66, 998-998.	7.3	1
83	Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC. Alimentary Pharmacology and Therapeutics, 2021, 53, 1329-1330.	3.7	1
84	The revival of preemptive UDCA therapy in liver transplant recipients. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101679.	1.5	0
85	Reply to: â€œChronic fatigue should not be overlooked in primary biliary cholangitisâ€• Journal of Hepatology, 2021, 75, 745.	3.7	0